Fleqsuvy FDA Approval History
FDA Approved: Yes (First approved February 4, 2022)
Brand name: Fleqsuvy
Generic name: baclofen
Dosage form: Oral Suspension
Company: Azurity Pharmaceuticals, Inc.
Treatment for: Spasticity
Fleqsuvy (baclofen) is an oral suspension formulation of baclofen for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity.
Development timeline for Fleqsuvy
| Date | Article |
|---|---|
| Feb 7, 2022 | Approval FDA Approves Fleqsuvy (baclofen oral suspension) for the Treatment of Spasticity |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
